AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28748386 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg subcutaneously every 6 months
Number of subjects: 285
Study 28748386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study 25324431 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (in-depth counseling from baseline to 3 months)
Number of subjects: 119
Study 25324431 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard advice on negative health outcomes)
Number of subjects: 119
Study 25324431 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (regardless of assignment)
Number of subjects: 119
Study 25324431 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 119
Study 25324431 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents who reported smoking fewer cigarettes
Number of subjects: 119
Study 22898037 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus bevacizumab (15 mg/kg on day 1 given intravenously every 21 days until disease progression)
Number of subjects: 46
Study 22898037 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus bevacizumab
Number of subjects: 46
Study 21471258 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine group (20 mL bupivacaine 0.25% and 0.5 mL adrenaline 1/200,000 each side)
Number of subjects: 70
Study 21471258 — intervention group
Group type: COMPARATOR
Intervention: Control group (20.5 mL normal saline each side)
Number of subjects: 70
Study 19398921 — intervention group
Group type: EXPERIMENTAL
Intervention: abacavir/lamivudine
Number of subjects: 333
Study 19398921 — intervention group
Group type: COMPARATOR
Intervention: tenofovir/emtricitabine
Number of subjects: 333
Study 16925535 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg massage prior to heel stick
Number of subjects: 23
Study 16925535 — intervention group
Group type: COMPARATOR
Intervention: No massage prior to heel stick
Number of subjects: 23
Study 15272109 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil of lavender
Number of subjects: 26
Study 15272109 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil of rosemary
Number of subjects: 26
Study 15272109 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 26
Study 11158752 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin 160 mg once daily for 7 days
Number of subjects: 0
Study 11158752 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin 320 mg once daily for 7 days
Number of subjects: 0
Study 11158752 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin 480 mg once daily for 7 days
Number of subjects: 0
Study 11158752 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin 640 mg once daily for 7 days
Number of subjects: 0
Study 11158752 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin (all doses)
Number of subjects: 0
Study 1335650 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine (SmithKline Beecham Biologicals)
Number of subjects: 260
Study 1335650 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B vaccine (control)
Number of subjects: 260
Study 6383220 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 0
Study 30513024 — intervention group
Group type: EXPERIMENTAL
Intervention: TargetMatch (TM)
Number of subjects: 10
Study 30513024 — intervention group
Group type: COMPARATOR
Intervention: FirstFit (FF)
Number of subjects: 10
Study 29397215 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect pulp capping (IPC)
Number of subjects: 302
Study 29397215 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct pulp capping (DPC)
Number of subjects: 302
Study 29397215 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniature pulpotomy (MP)
Number of subjects: 302
Study 29397215 — intervention group
Group type: EXPERIMENTAL
Intervention: Full pulpotomy (FP)
Number of subjects: 302
Study 27109264 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine (6 g)
Number of subjects: 17
Study 27109264 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6 g dextrose)
Number of subjects: 17
Study 25509728 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment group
Number of subjects: 30
Study 25509728 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 30
Study 22313205 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D electromagnetic navigation system
Number of subjects: 17
Study 22313205 — intervention group
Group type: COMPARATOR
Intervention: Standard EVAR procedure (Control)
Number of subjects: 17
Study 20659194 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cryotherapy
Number of subjects: 0
Study 20659194 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 18327081 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Na-high K diet
Number of subjects: 40
Study 18327081 — intervention group
Group type: COMPARATOR
Intervention: High Na-low K diet
Number of subjects: 40
Study 15943592 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone (30 microg/m(2) body surface area/24 h)
Number of subjects: 16
Study 15943592 — intervention group
Group type: COMPARATOR
Intervention: Saline (as a placebo)
Number of subjects: 16
Study 12861239 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated Progressive Muscle Relaxation Therapy (APRT)
Number of subjects: 20
Study 12861239 — intervention group
Group type: COMPARATOR
Intervention: Control (quietly sitting for the same amount of time)
Number of subjects: 20
Study 10774661 — intervention group
Group type: EXPERIMENTAL
Intervention: SB MMR vaccine
Number of subjects: 700
Study 10774661 — intervention group
Group type: COMPARATOR
Intervention: Merck MMR vaccine
Number of subjects: 700
Study 8683240 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (160 mg orally daily for 7 days before chemotherapy and 40 mg orally daily throughout the treatment cycle)
Number of subjects: 199
Study 8683240 — intervention group
Group type: COMPARATOR
Intervention: Placebo (given with the same chemotherapy regimen)
Number of subjects: 199
Study 1929686 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrone sulfate 0.3 mg
Number of subjects: 120
Study 1929686 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrone sulfate 0.625 mg
Number of subjects: 120
Study 1929686 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrone sulfate 1.25 mg
Number of subjects: 120
Study 1929686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 3881155 — intervention group
Group type: EXPERIMENTAL
Intervention: Incision, curettage and primary suture without parenteral antibiotics (64 cases)
Number of subjects: 137
Study 3881155 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment with incision, drainage and dressings (73 cases)
Number of subjects: 137
Study 29981863 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent DOAC use guided by continuous remote AF monitoring via dual-chamber pacemakers or implantable cardioverter-defibrillators (ICDs)
Number of subjects: 48
Study 29981863 — intervention group
Group type: COMPARATOR
Intervention: Control group (chronic DOAC administration)
Number of subjects: 48
Study 27625094 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2b
Number of subjects: 58
Study 27625094 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term follow-up (LTFU)
Number of subjects: 58
Study 24996988 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous morphine infusion
Number of subjects: 0
Study 24996988 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (placebo)
Number of subjects: 0
Study 22145978 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional SLA implants
Number of subjects: 24
Study 22145978 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemically modified SLA (modSLA) implants
Number of subjects: 24
Study 22145978 — intervention group
Group type: COMPARATOR
Intervention: Both implant types
Number of subjects: 24
Study 21565967 — intervention group
Group type: EXPERIMENTAL
Intervention: HI‐NPPV (mean inspiratory positive airway pressure 29 ± 4 mbar)
Number of subjects: 17
Study 21565967 — intervention group
Group type: COMPARATOR
Intervention: LI‐NPPV (mean inspiratory positive airway pressure 14 mbar)
Number of subjects: 17
Study 21565967 — intervention group
Group type: EXPERIMENTAL
Intervention: HI‐NPPV
Number of subjects: 17
Study 21565967 — intervention group
Group type: COMPARATOR
Intervention: LI‐NPPV
Number of subjects: 17
Study 18461212 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week exercise training programme (2 sessions per week of 45 to 60 minutes of circuit-based resistance training and aerobic exercises at 65% to 85% HRmax)
Number of subjects: 24
Study 18461212 — intervention group
Group type: COMPARATOR
Intervention: Control group (typical 2 sessions of 40-minute physical education per week)
Number of subjects: 24
Study 18461212 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week exercise training programme
Number of subjects: 24
Study 16582851 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBMP-2
Number of subjects: 131
Study 16582851 — intervention group
Group type: COMPARATOR
Intervention: autologous bone graft (Control)
Number of subjects: 131
Study 12707465 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous therapy (3-5 mg/kg/day initially, then 0.5-3 mg/kg/day after remission)
Number of subjects: 31
Study 12707465 — intervention group
Group type: COMPARATOR
Intervention: Intermittent therapy (3-5 mg/kg/day initially, then tapered off after remission)
Number of subjects: 31
Study 12707465 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 31
Study 10784478 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex treatment for 6 weeks
Number of subjects: 20
Study 10784478 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 20
Study 10784478 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex treatment for 6 weeks (in subjects who completed both phases)
Number of subjects: 20
Study 8982753 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol patch (100 micrograms/day for 6 weeks)
Number of subjects: 64
Study 8982753 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 64
Study 8982753 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol patch
Number of subjects: 64
Study 1290019 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon gamma (IFN-gamma)
Number of subjects: 249
Study 1290019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study 6150945 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg metoprolol
Number of subjects: 8
Study 6150945 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg nadolol
Number of subjects: 8
Study 6150945 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg propranolol
Number of subjects: 8
Study 6150945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30144016 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II
Number of subjects: 0
Study 30144016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30203757 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure plus high-dose ambroxol
Number of subjects: 200
Study 26263283 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/hour nitroglycerin patch applied daily, escalating to 0.2, 0.4, or 0.6 mg/hour as tolerated
Number of subjects: 19
Study 26263283 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of nitroglycerin
Number of subjects: 19
Study 24756122 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone hydrogel bandage contact lenses (BCLs)
Number of subjects: 39
Study 24756122 — intervention group
Group type: COMPARATOR
Intervention: Control (no BCLs)
Number of subjects: 39
Study 22309675 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 40
Study 22309675 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle changes
Number of subjects: 40
Study 20418533 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (Group S)
Number of subjects: 78
Study 20418533 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil-sevoflurane (Group R)
Number of subjects: 78
Study 17401735 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 0
Study 17401735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17401735 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual tasking
Number of subjects: 0
Study 17401735 — intervention group
Group type: EXPERIMENTAL
Intervention: Single task condition
Number of subjects: 0
Study 16250191 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified transition concept (therapeutic weekend care, bedside teaching, structured information for relatives)
Number of subjects: 62
Study 16250191 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified transition concept
Number of subjects: 62
Study 16250191 — intervention group
Group type: COMPARATOR
Intervention: Standard transition
Number of subjects: 62
Study 12151907 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 116
Study 12151907 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 116
Study 10225643 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot pack rewarming
Number of subjects: 134
Study 10225643 — intervention group
Group type: COMPARATOR
Intervention: Routine care only (passive or no warming)
Number of subjects: 134
Study 10225643 — intervention group
Group type: COMPARATOR
Intervention: Passive warming
Number of subjects: 134
Study 10225643 — intervention group
Group type: COMPARATOR
Intervention: Reflective blankets
Number of subjects: 134
Study 10225643 — intervention group
Group type: COMPARATOR
Intervention: Warmed IV fluids
Number of subjects: 134
Study 10225643 — intervention group
Group type: COMPARATOR
Intervention: Warmed IV fluid plus reflective blanket
Number of subjects: 134
Study 7600653 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (up to 25 mg BID)
Number of subjects: 415
Study 7600653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 415
Study 2194642 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (2.0 mg/kg) and Lorazepam (1.5 mg/m2) without Dexamethasone
Number of subjects: 37
Study 2194642 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (2.0 mg/kg) and Lorazepam (1.5 mg/m2) with Dexamethasone (0.5 mg/kg)
Number of subjects: 37
Study 221114 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic alternating combination chemotherapy with high‐dose cyclophosphamide, methotrexate, and CCNU (CMC) followed by vincristine, adriamycin, and procarbazine (VAP) for 6 weeks each.
Number of subjects: 61
Study 221114 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of VAP after CMC treatment.
Number of subjects: 61
Study 221114 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of VO‐16‐213 and ifosfamide for half of the patients.
Number of subjects: 61
Study 221114 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete responders only.
Number of subjects: 61
Study 30278430 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol 100 mg/d
Number of subjects: 71
Study 30278430 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sucrose 0.5 g/d)
Number of subjects: 71
Study 28598661 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrier control
Number of subjects: 0
Study 28598661 — intervention group
Group type: COMPARATOR
Intervention: Tilt control
Number of subjects: 0
Study 28598661 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrier control with optimized composite pulses
Number of subjects: 0
Study 25761202 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM) data analysis
Number of subjects: 45
Study 23328268 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel napadisilate plus aspirin
Number of subjects: 127
Study 23328268 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel bisulfate plus aspirin
Number of subjects: 127
Study 22026966 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined diet + exercise
Number of subjects: 439
Study 22026966 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 439
Study 22026966 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 439
Study 22026966 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 439
Study 19210039 — intervention group
Group type: EXPERIMENTAL
Intervention: SLDT and ISW
Number of subjects: 0
Study 19210039 — intervention group
Group type: EXPERIMENTAL
Intervention: Other methods of assessing premorbid cognitive function
Number of subjects: 0
Study 16580587 — intervention group
Group type: EXPERIMENTAL
Intervention: Pistachio diet (substituting pistachio nuts for 20% of daily caloric intake for 3 weeks)
Number of subjects: 44
Study 16580587 — intervention group
Group type: COMPARATOR
Intervention: Regular diet
Number of subjects: 44
Study 14508717 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim (Neulasta)
Number of subjects: 0
Study 14508717 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim (r‐metHuG‐CSF)
Number of subjects: 0
Study 10902094 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0
Study 10902094 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychostimulants
Number of subjects: 0
Study 10902094 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0
Study 10902094 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0
Study 10902094 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalfrexone
Number of subjects: 0
Study 10902094 — intervention group
Group type: COMPARATOR
Intervention: Secretin
Number of subjects: 0
Study 10902094 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin-reuptake inhibitors
Number of subjects: 0
Study 10902094 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone, mood stabilizers, beta-blockers
Number of subjects: 0
Study 9229615 — intervention group
Group type: EXPERIMENTAL
Intervention: Cordipin chronotherapy (10 mg once a day based on chronosensitivity)
Number of subjects: 40
Study 9229615 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment with cordipin (10 mg 3 times a day)
Number of subjects: 40
Study 8447919 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-minute stations
Number of subjects: 36
Study 8447919 — intervention group
Group type: EXPERIMENTAL
Intervention: Ten-minute stations
Number of subjects: 36
Study 8447919 — intervention group
Group type: EXPERIMENTAL
Intervention: Checklist subscores
Number of subjects: 36
Study 8447919 — intervention group
Group type: EXPERIMENTAL
Intervention: Couplet subscores
Number of subjects: 36
Study 2934557 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg adjuvant medroxyprogesterone 3 times a week for 1 year
Number of subjects: 136
Study 2934557 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 136
Study 28557043 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led psychological intervention programme (seven weekly counselling sessions)
Number of subjects: 60
Study 28557043 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 26578543 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI) for weight loss
Number of subjects: 3214
Study 26578543 — intervention group
Group type: COMPARATOR
Intervention: Diabetes mellitus support and education
Number of subjects: 3214
Study 25550013 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood injection (2 ml of autologous venous blood mixed with 1 ml of 2% prilocaine hydrochloride)
Number of subjects: 80
Study 25550013 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection (1 ml of 40 mg methylprednisolone acetate mixed with 1 ml of 2% prilocaine hydrochloride)
Number of subjects: 80
Study 22413836 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 499
Study 22413836 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 499
Study 22413836 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted averages of all four methods
Number of subjects: 499
Study 22413836 — intervention group
Group type: COMPARATOR
Intervention: Office BP measurement
Number of subjects: 499
Study 22413836 — intervention group
Group type: COMPARATOR
Intervention: Ambulatory nighttime BP measurement
Number of subjects: 499
Study 20511285 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based CBT intervention
Number of subjects: 96
Study 20511285 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 96
Study 18456384 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy
Number of subjects: 125
Study 18456384 — intervention group
Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 125
Study 18456384 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress-coping ability (measured preoperatively)
Number of subjects: 125
Study 18456384 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative complications
Number of subjects: 125
Study 18456384 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress-coping ability
Number of subjects: 125
Study 14709512 — intervention group
Group type: EXPERIMENTAL
Intervention: Body composition measurement using dual energy x ray absorptiometry (DEXA) and bioelectrical impedance analysis (BIA)
Number of subjects: 35
Study 14709512 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA)
Number of subjects: 35
Study 11732218 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd-YAG laser capsulotomy
Number of subjects: 54
Study 11732218 — intervention group
Group type: COMPARATOR
Intervention: Topical Beta-blockers and steroids
Number of subjects: 54
Study 9126899 — intervention group
Group type: EXPERIMENTAL
Intervention: Transluminal angioplasty
Number of subjects: 14
Study 9126899 — intervention group
Group type: COMPARATOR
Intervention: Intraarterial papaverine (compared with no papaverine)
Number of subjects: 14
Study 7952921 — intervention group
Group type: COMPARATOR
Intervention: Lymphocyte transformation assay for serovar A
Number of subjects: 20